Skip to main content

Peer Review reports

From: Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

Original Submission
12 Sep 2017 Submitted Original manuscript
20 Oct 2017 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 2
20 Oct 2017 Submitted Manuscript version 2
23 May 2018 Reviewed Reviewer Report - Fang Yang
31 May 2018 Reviewed Reviewer Report - Marzia Locatelli
28 Jun 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 3
28 Jun 2018 Submitted Manuscript version 3
10 Jul 2018 Reviewed Reviewer Report - Marzia Locatelli
8 Aug 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 4
8 Aug 2018 Submitted Manuscript version 4
8 Oct 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 5
8 Oct 2018 Submitted Manuscript version 5
10 Oct 2018 Author responded Author comments - Gabriel Rinnerthaler
Resubmission - Version 6
10 Oct 2018 Submitted Manuscript version 6
Publishing
21 Oct 2018 Editorially accepted
6 Nov 2018 Article published 10.1186/s12885-018-4979-0

You can find further information about peer review here.

Back to article page